|Mr. Hugh O'Dowd||Pres, CEO & Director||688.75k||N/A||1965|
|Dr. Eric S. Lander||Director||69.71k||N/A||1957|
|Dr. Yasir B. Al-Wakeel||Chief Financial Officer||529.93k||N/A||1982|
|Dr. Richard Gaynor||Pres of R&D||536.77k||N/A||1950|
|Dr. Edward Fritsch||Founder & CTO||N/A||N/A||N/A|
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Neon Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.